Tecan acquires ELISA kit assets from Cisbio Bioassays

Tecan Group agreed to acquire certain assets relating to four ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of Revvity. The asset purchase includes the manufacturing process of two IVD kits and two RUO kits.

“This strategic purchase aligns with our commitment to supporting customers with high-quality solutions while strengthening our portfolio in specialty diagnostics.”news-medical.net

• 1 source
• news-medical.netTecan expands portfolio for specialty diagnostics with an asset purchase relating to certain ELISA kitsNews MedicalApr 7, 2025

Summarized from public sources; check the original articles before acting on it.